Alto Neuroscience Inc. (ANRO) Stock Price
ANROStock
$35.13+822.05%52W
Market Cap$1.38B
P/E—
PEG Ratio—
Div yield—
Beta1.23
ANRO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)69.90%
Price vs S&P 500 (4W)27.28%
VGM Score85.10
ANRO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.77 | -$0.65 | +15.95%(+$0.12) | |
| Q1 2026 | -$0.51 | -$0.80 | -58.42%(-$0.30) | |
| Q4 2025 | -$0.51 | -$0.45 | +11.76%(+$0.06) | |
| Q3 2025 | -$0.64 | -$0.52 | +18.75%(+$0.12) | |
| Q2 2025 | -$0.60 | -$0.65 | -8.56%(-$0.05) |
ANRO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.31
4.39
4.39
4.38
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANROAlto Neuroscience Inc. | — | — | A | $35.13 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Alto Neuroscience Inc.
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments guided by brain-based biomarkers. The company's pipeline includes multiple programs targeting major depressive disorder and schizophrenia, with candidates including ALTO-100, ALTO-202, ALTO-101, and ALTO-300. Alto's approach aims to match patients with treatments based on individual neurobiology to improve treatment efficacy in psychiatry.